ReviewPhytotherapy research : PTR2026
Marine Algae and Neuroprotection: Unlocking the Therapeutic Potential Against Neurodegenerative Diseases.
Review in Phytotherapy research : PTR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Neurodegenerative diseases (NDDs) are recognized by the World Health Organization as the second leading cause of mortality worldwide, and their prevalence continues to rise at an alarming rate. Current treatment strategies primarily provide symptomatic relief without effectively targeting the complex and multifactorial pathogenesis of NDDs, which involves oxidative stress, neuroinflammation, mitochondrial dysfunction, and abnormal protein aggregation. Therefore, there is an urgent need for novel, multi-target therapeutic strategies. In recent years, marine biodiversity has gained growing attention as a rich reservoir of pharmacologically active natural products. Marine algae, in particular, contain diverse bioactive metabolites including polyphenols, polysaccharides, carotenoids, and phlorotannins, many of which exhibit potent neuroprotective properties. To address the existing knowledge void and limitations, we propose to present a thorough review that updates information on the neuroprotective effects of marine algal compounds and their therapeutic advancements. For this, about 31800 articles were reviewed via databases like PubMed, Science Direct, Google Scholar, and Web of Science. They were reduced to 1263 using MeSH words like 'marine algae, neurodegeneration, and neuroprotection' coupled with Boolean operators. The compiled findings demonstrated that marine algal compounds modulate multiple neuroprotective pathways, including PI3K/Akt, Nrf2/HO-1, and PKA/CREB/BDNF, and exert antioxidant, anti-inflammatory, anti-amyloidogenic, and neurotrophic effects. These multifaceted mechanisms highlight their potential in mitigating key pathological processes associated with NDDs. In conclusion Marine algae represent a promising yet underexplored source of phytotherapeutic agents. Further preclinical and clinical investigations are warranted to validate their efficacy and advance their development as potential neuroprotective therapeutics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.